Peiwen Ma

Preclinical characterization and first-in-human phase I dose-escalation results with JYB1907, a novel anti-GARP-TGF-β1 complex monoclonal antibody in patients with advanced solid tumors

Transforming growth factor-β1 (TGF-β1) promotes immunosuppression in the tumor microenvironment via the GARP-latent TGF-β1 complex on regulatory T cells. JYB1907 is a humanized IgG4 monoclonal antibody targeting this complex. Preclinically, JYB1907 bound GARP-latent TGF-β1 comple...